Skip to main content

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Calian Group Ltd. (CGY-T) announced that it has been selected by the Department of National Defence (DND) to provide “as and when requested” science and technology (S&T) research capabilities.

The company said it has been awarded the contract under the Canadian Safety and Security Program (CSSP) at Defence Research and Development Canada (DRDC).

Story continues below advertisement

Calian said it will support technology services for CSSP and about 21 federal departments and agencies, “providing the ability to scale up Canada’s science and technology capabilities to meet specific operational requirements.”

The contract has a term of up to five years and is valued at approximately $18-million.

**

AGF Management Limited (AGF.B-T) announced total assets under management (AUM) of $37-billion as of its third quarter ended Aug. 31 compared to $37.4-billion in the same period in 2019.

It said average daily mutual fund AUM remained flat at $18.9-billion compared to the same period in 2019.

Net mutual fund redemptions of $22-million compared to net redemptions of $103-million a year ago, the company said.

Income was $138.7-million, compared to $107.4-million in the prior year and above expectations of $113.4-million.

Story continues below advertisement

Net income of $47.3-million or 60 cents per share compared to $14.4-million or 18 cents a year ago. Adjusted net income was $14.8-million or 19 cents versus $14.6-million or 18 cents a year ago. Analysts were expecting adjusted EPS of 14 cents.

**

Aurora Cannabis Inc. (ACB-N; ACB-T) reported revenue of $72.1-million for its fourth quarter ended June 30, a 5-per-cent decrease from the prior quarter. The expectation was for revenue of $71.5-million.

Its net loss from continuing operations was $1.86-billion. The company said it recorded “a number of balance sheet adjustments” in the quarter in “to recognize market realities and position the company for future performance.” It recognized a non-cash write-down of goodwill and intangible assets of $1.6-billion, a $135.1-million inventory charge and an $86.5-million writedown on its production facilities.

Recently appointed chief executive officer Miguel Martin said the fourth quarter “demonstrated progress in rationalization of SG&A [selling, general and administrative expenses] and cash burn along with continued leadership in both Canadian and international medical. However, Aurora has slipped from its top position in Canadian consumer, a market that continues to support material growth and opportunity.”

Mr. Martin said his focus is to “re-position the Canadian consumer business immediately.”

Story continues below advertisement

In its outlook, the company said net revenue — which will just be from cannabis revenue after divestitures — is expected to be between $60-million and $64-million, compared to $67.5-million of cannabis-only revenue in the fourth quarter.

The company also said it expects to achieve positive adjusted EBITDA in the second quarter of 2021.

**

WildBrain Ltd. (WILD-T) reported fourth-quarter revenue was $92.9-million versus $108.8-million in Q4 2019. Analysts were expecting revenue of $91.8-million.

Net income of $4-million or 2 cents per share compared to as a net loss of $62.8-million or 47 cents a year ago.

**

Story continues below advertisement

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies